Production (Stage)
Elite Pharmaceuticals, Inc.
ELTP
$0.517
-$0.0022-0.42%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 48.42% | 47.93% | 73.47% | 87.40% | 65.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 48.42% | 47.93% | 73.47% | 87.40% | 65.81% |
| Cost of Revenue | 45.23% | 52.46% | 83.23% | 96.35% | 68.46% |
| Gross Profit | 52.09% | 42.57% | 62.75% | 77.62% | 62.87% |
| SG&A Expenses | 26.34% | 62.82% | 60.54% | 57.64% | 49.10% |
| Depreciation & Amortization | 22.36% | 24.87% | 20.51% | 14.03% | 9.21% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.10% | 43.29% | 58.72% | 72.75% | 51.87% |
| Operating Income | 96.54% | 74.78% | 170.94% | 186.95% | 171.84% |
| Income Before Tax | -111.25% | -626.22% | -1,044.24% | -99.72% | -88.38% |
| Income Tax Expenses | 121.70% | 103.66% | 97.75% | -3,479.12% | -4,732.28% |
| Earnings from Continuing Operations | -121.46% | -215.64% | -135.85% | 345.29% | 464.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -121.46% | -215.64% | -135.85% | 345.29% | 464.57% |
| EBIT | 96.54% | 74.78% | 170.94% | 186.95% | 171.84% |
| EBITDA | 88.33% | 66.41% | 141.21% | 148.25% | 132.32% |
| EPS Basic | -120.20% | -208.50% | -132.57% | 348.84% | 465.71% |
| Normalized Basic EPS | 212.50% | -339.13% | -- | -142.31% | -140.00% |
| EPS Diluted | -133.61% | -294.12% | -171.77% | 192.31% | 283.87% |
| Normalized Diluted EPS | 212.50% | -339.13% | -- | -142.31% | -140.00% |
| Average Basic Shares Outstanding | 5.21% | 4.12% | 2.82% | 1.52% | 0.24% |
| Average Diluted Shares Outstanding | 4.60% | 4.29% | 3.48% | 2.45% | 1.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |